Chirag M. Vyas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chirag M. Vyas has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Olivia I. Okereke
Department of Psychiatry, Massachusetts General Brigham, Boston, USA
8 shared publications David Mischoulon
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
7 shared publicationsJoAnn E. Manson
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA
7 shared publicationsGrace Chang
VA Boston Healthcare System, Harvard Medical School, Boston, MA USA
6 shared publicationsOlivia I. Okereke
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, USA
6 shared publicationsCharles F. Reynolds
University of Pittsburgh Medical Center, Pittsburgh, PA USA
5 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Elsevier in Comprehensive Psychoneuroendocrinology
- Vol. 28, 100389
Childhood maltreatment and hair cortisol in pregnancy: role of recent stress
- 2 November 2026
- Published by Elsevier in Comprehensive Psychoneuroendocrinology
- Vol. 28, 100389
Open AccessChildhood maltreatment and hair cortisol in pregnancy: role of recent stress
- 11 May 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 35 (9) , 2769-2778
The relation between household dogs and cats during childhood/adolescence with social role outcomes and loneliness among youth with attention-deficit/hyperactivity disorder
Attention-deficit/hyperactivity disorder (ADHD) is associated with social role dysfunction and loneliness. Household dogs and cats may facilitate social interactions and emotional support, but little is known about their associatons with social role function and loneliness among youth with ADHD. In this study, we addressed these associations in 1056 participants from the Growing Up Today Study (GUTS), a cohort of children from the Nurses’ Health Study (NHS)II. ADHD was determined using maternal reports and participants’ self-reports of diagnosis and/or treatment. Pet ownership was assessed during childhood and early adolescence in the 1999 questionnaire, with categories: (1) Dog and cat; (2) Dog but no cat; (3) Cat but no dog; (4) No dog or cat. Outcomes included overall social role functioning (assessed in 2013), quality of interpersonal relationships with mothers (2005) and romantic partners (2010), and loneliness (assessed repeatedly between 2007 and 2016). Overall social role functioning was analyzed using the chi-square test; quality of interpersonal relationships and loneliness were analyzed using generalized mixed models. No significant differences were observed in overall social role functioning across pet categories. Compared to those who had no dog or cat, dog and/or cat owners did not differ in their likelihood of reporting high-quality interpersonal relationships. Similarly, dog and/or cat ownership was not associated with lower likelihood of loneliness compared to those who had no dog or cat. Future studies could examine repeated measures of pet ownership and other aspects of pet ownership, such as emotional attachment, to clarify potential associations with social and psychological outcomes.
- 11 May 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 35 (9) , 2769-2778
The relation between household dogs and cats during childhood/adolescence with social role outcomes and loneliness among youth with attention-deficit/hyperactivity disorder
Attention-deficit/hyperactivity disorder (ADHD) is associated with social role dysfunction and loneliness. Household dogs and cats may facilitate social interactions and emotional support, but little is known about their associatons with social role function and loneliness among youth with ADHD. In this study, we addressed these associations in 1056 participants from the Growing Up Today Study (GUTS), a cohort of children from the Nurses’ Health Study (NHS)II. ADHD was determined using maternal reports and participants’ self-reports of diagnosis and/or treatment. Pet ownership was assessed during childhood and early adolescence in the 1999 questionnaire, with categories: (1) Dog and cat; (2) Dog but no cat; (3) Cat but no dog; (4) No dog or cat. Outcomes included overall social role functioning (assessed in 2013), quality of interpersonal relationships with mothers (2005) and romantic partners (2010), and loneliness (assessed repeatedly between 2007 and 2016). Overall social role functioning was analyzed using the chi-square test; quality of interpersonal relationships and loneliness were analyzed using generalized mixed models. No significant differences were observed in overall social role functioning across pet categories. Compared to those who had no dog or cat, dog and/or cat owners did not differ in their likelihood of reporting high-quality interpersonal relationships. Similarly, dog and/or cat ownership was not associated with lower likelihood of loneliness compared to those who had no dog or cat. Future studies could examine repeated measures of pet ownership and other aspects of pet ownership, such as emotional attachment, to clarify potential associations with social and psychological outcomes.
- Open Access
- 25 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Associations between women’s childhood maltreatment and thyroid function before and during pregnancy
Maternal childhood maltreatment has been associated with complications during pregnancy and neurodevelopmental disorders in offspring. Thyroid dysfunction could be a mechanistic pathway underlying this relationship. The thyroid is vital for reproductive health in women, maintaining menstrual cycles, fertility, and pregnancy. However, little is known how childhood maltreatment affects thyroid function in women contemplating pregnancy and those who are pregnant. Participants were from the Nurses’ Health Study 3, including 217 women contemplating pregnancy and 156 pregnant women, all reporting childhood maltreatment using a validated 28-item Childhood Trauma Questionnaire. Thyroid function tests were plasma thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), and anti-thyroperoxidase antibody (TPOAb). Regression analyses were conducted. Among women contemplating pregnancy (n = 217), childhood maltreatment was consistently associated with lower FT3 levels, but not with FT4, TSH, or TPOAb levels. FT3 levels were 5% to 7% lower in those with mild to severe childhood maltreatment compared to those without. Among pregnant women (n = 156), no significant associations were observed between childhood maltreatment and thyroid function. In conclusion, childhood maltreatment was associated with low thyroid function (e.g., FT3) among women contemplating pregnancy, but not among pregnant women. Future large, prospective, racially and ethnically diverse studies are needed to confirm our findings.
- 25 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAssociations between women’s childhood maltreatment and thyroid function before and during pregnancy
Maternal childhood maltreatment has been associated with complications during pregnancy and neurodevelopmental disorders in offspring. Thyroid dysfunction could be a mechanistic pathway underlying this relationship. The thyroid is vital for reproductive health in women, maintaining menstrual cycles, fertility, and pregnancy. However, little is known how childhood maltreatment affects thyroid function in women contemplating pregnancy and those who are pregnant. Participants were from the Nurses’ Health Study 3, including 217 women contemplating pregnancy and 156 pregnant women, all reporting childhood maltreatment using a validated 28-item Childhood Trauma Questionnaire. Thyroid function tests were plasma thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), and anti-thyroperoxidase antibody (TPOAb). Regression analyses were conducted. Among women contemplating pregnancy (n = 217), childhood maltreatment was consistently associated with lower FT3 levels, but not with FT4, TSH, or TPOAb levels. FT3 levels were 5% to 7% lower in those with mild to severe childhood maltreatment compared to those without. Among pregnant women (n = 156), no significant associations were observed between childhood maltreatment and thyroid function. In conclusion, childhood maltreatment was associated with low thyroid function (e.g., FT3) among women contemplating pregnancy, but not among pregnant women. Future large, prospective, racially and ethnically diverse studies are needed to confirm our findings.
- Open Access
- 8 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331905
Estimating the associations between women’s maltreatment in childhood and inflammatory biomarker levels prior to and during pregnancy
Background: Maternal childhood maltreatment has been associated with higher risk of adverse neurodevelopment in offspring. Chronic systemic inflammation has been associated with childhood maltreatment and has been identified as a gestational risk factor for adverse neurodevelopment in offspring. Thus, inflammation may be a mechanism by which maternal exposure to maltreatment affects offspring neurodevelopment. To estimate associations between women’s childhood maltreatment and four inflammatory biomarkers, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha receptor 2 (TNF-R2), and interferon gamma (IFN-γ), among women prior to or during pregnancy. Methods: A sub-study of the Nurses’ Health Study 3, a prospective cohort, included 329 women, 204 who were contemplating pregnancy and 124 who were pregnant. Approximately 90% of participants were non-Hispanic White and over 60% had a Master’s degree or higher. Maltreatment was assessed using the validated 28-item Childhood Trauma Questionnaire. Associations were calculated using generalized estimating equations. Results: Fifty participants (15.2%) were not exposed abuse (n = 28 contemplating pregnancy; n = 22 pregnant) and 81 participants (24.6%) were exposed to moderate or severe abuse (n = 55 contemplating pregnancy; n = 26 pregnant). Childhood maltreatment was not associated with the four inflammatory biomarkers either among participants contemplating pregnancy or among pregnant participants. Conclusions: No statistically significant associations were identified between childhood maltreatment and selected inflammatory biomarkers in this sample of well-educated, primarily non-Hispanic White women. These findings should be interpreted with caution given the limited statistical power and measurement variability. Further investigation of these associations in more vulnerable populations might enhance our understanding of biological mechanisms linking maternal childhood abuse to adverse neurodevelopment in offspring.
- 8 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331905
Open AccessEstimating the associations between women’s maltreatment in childhood and inflammatory biomarker levels prior to and during pregnancy
Background: Maternal childhood maltreatment has been associated with higher risk of adverse neurodevelopment in offspring. Chronic systemic inflammation has been associated with childhood maltreatment and has been identified as a gestational risk factor for adverse neurodevelopment in offspring. Thus, inflammation may be a mechanism by which maternal exposure to maltreatment affects offspring neurodevelopment. To estimate associations between women’s childhood maltreatment and four inflammatory biomarkers, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha receptor 2 (TNF-R2), and interferon gamma (IFN-γ), among women prior to or during pregnancy. Methods: A sub-study of the Nurses’ Health Study 3, a prospective cohort, included 329 women, 204 who were contemplating pregnancy and 124 who were pregnant. Approximately 90% of participants were non-Hispanic White and over 60% had a Master’s degree or higher. Maltreatment was assessed using the validated 28-item Childhood Trauma Questionnaire. Associations were calculated using generalized estimating equations. Results: Fifty participants (15.2%) were not exposed abuse (n = 28 contemplating pregnancy; n = 22 pregnant) and 81 participants (24.6%) were exposed to moderate or severe abuse (n = 55 contemplating pregnancy; n = 26 pregnant). Childhood maltreatment was not associated with the four inflammatory biomarkers either among participants contemplating pregnancy or among pregnant participants. Conclusions: No statistically significant associations were identified between childhood maltreatment and selected inflammatory biomarkers in this sample of well-educated, primarily non-Hispanic White women. These findings should be interpreted with caution given the limited statistical power and measurement variability. Further investigation of these associations in more vulnerable populations might enhance our understanding of biological mechanisms linking maternal childhood abuse to adverse neurodevelopment in offspring.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2)
Treatment effects of vitamin D3 and marine omega‐3 fatty acids on plasma ADRD biomarkers: Exploring sex and race differences
Background: There is an urgent need to identify novel, accessible and affordable strategies to prevent cognitive decline and progression in the Alzheimer disease and related dementias (ADRD) continuum. Vitamin D3 and marine omega‐3 fatty acids (omega‐3s) supplements show promise for cognitive protection, with potential variations in their effects by sex or race. However, to date, no randomized clinical trials (RCTs) have tested their impact on emerging plasma‐based biomarkers with potential utility to predict ADRD pathogenesis.Methods: Vitamin D and Omega‐3 Trial (VITAL) is a completed, nation‐wide, 2x2 factorial placebo‐controlled RCT testing vitamin D3 (2000 IU/d) and omega‐3s (1 g/d) for cancer and cardiovascular disease prevention. We included a Boston‐area sub‐cohort of 929 randomized VITAL participants who provided blood samples at baseline, 2‐year, and/or 4‐year follow‐up. Plasma ADRD biomarkers, including an N‐terminal tau fragment (NT1), amyloid‐β (Aβ)‐40, Aβ‐42, neurofilament‐light (NfL), and glial fibrillary acidic protein (GFAP), were measured. We used multivariable‐adjusted repeated measures models for data analysis; sex and race were pre‐specified effect modifiers.Results: Among 929 participants, the mean age was 65 years; 49.2% were females; 17.3% were from racial and/or ethnic minority backgrounds, including 8.2% Black adults. Neither vitamin D3 nor omega‐3s, compared to placebo, significantly reduced ADRD biomarkers overall across 4 years of treatment; however, there was a trend for reduction in Aβ‐40:Aβ‐42 ratio over 4 years for vitamin D3 versus placebo [percent difference (95% confidence interval [CI]): ‐1.2 (‐2.7, 0.3)]. Subgroup analyses uncorrected for multiple‐testing suggested interactions by sex and race. Vitamin D3 versus placebo resulted in a reduction in NT1 among males (‐2.7%) but not females (p‐interaction=0.08). Among Black participants, vitamin D3 versus placebo resulted in a 16% reduction in NfL levels [95% CI, ‐30.5% to 1.1%; p‐interaction=0.06], while omega‐3s versus placebo showed a 12.4% reduction in GFAP levels [95% CI, ‐21.5% to ‐2.2%; p‐interaction=0.049].Conclusion: In this RCT sub‐cohort of 929 older adults, neither vitamin D3 nor omega‐3s supplements significantly reduced selected plasma ADRD biomarkers over 4 years. We observed potential differences by sex and race in reductions of some ADRD biomarkers in response to these supplements which warrant further investigation in a larger sample.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2)
Open AccessTreatment effects of vitamin D3 and marine omega‐3 fatty acids on plasma ADRD biomarkers: Exploring sex and race differences
Background: There is an urgent need to identify novel, accessible and affordable strategies to prevent cognitive decline and progression in the Alzheimer disease and related dementias (ADRD) continuum. Vitamin D3 and marine omega‐3 fatty acids (omega‐3s) supplements show promise for cognitive protection, with potential variations in their effects by sex or race. However, to date, no randomized clinical trials (RCTs) have tested their impact on emerging plasma‐based biomarkers with potential utility to predict ADRD pathogenesis.Methods: Vitamin D and Omega‐3 Trial (VITAL) is a completed, nation‐wide, 2x2 factorial placebo‐controlled RCT testing vitamin D3 (2000 IU/d) and omega‐3s (1 g/d) for cancer and cardiovascular disease prevention. We included a Boston‐area sub‐cohort of 929 randomized VITAL participants who provided blood samples at baseline, 2‐year, and/or 4‐year follow‐up. Plasma ADRD biomarkers, including an N‐terminal tau fragment (NT1), amyloid‐β (Aβ)‐40, Aβ‐42, neurofilament‐light (NfL), and glial fibrillary acidic protein (GFAP), were measured. We used multivariable‐adjusted repeated measures models for data analysis; sex and race were pre‐specified effect modifiers.Results: Among 929 participants, the mean age was 65 years; 49.2% were females; 17.3% were from racial and/or ethnic minority backgrounds, including 8.2% Black adults. Neither vitamin D3 nor omega‐3s, compared to placebo, significantly reduced ADRD biomarkers overall across 4 years of treatment; however, there was a trend for reduction in Aβ‐40:Aβ‐42 ratio over 4 years for vitamin D3 versus placebo [percent difference (95% confidence interval [CI]): ‐1.2 (‐2.7, 0.3)]. Subgroup analyses uncorrected for multiple‐testing suggested interactions by sex and race. Vitamin D3 versus placebo resulted in a reduction in NT1 among males (‐2.7%) but not females (p‐interaction=0.08). Among Black participants, vitamin D3 versus placebo resulted in a 16% reduction in NfL levels [95% CI, ‐30.5% to 1.1%; p‐interaction=0.06], while omega‐3s versus placebo showed a 12.4% reduction in GFAP levels [95% CI, ‐21.5% to ‐2.2%; p‐interaction=0.049].Conclusion: In this RCT sub‐cohort of 929 older adults, neither vitamin D3 nor omega‐3s supplements significantly reduced selected plasma ADRD biomarkers over 4 years. We observed potential differences by sex and race in reductions of some ADRD biomarkers in response to these supplements which warrant further investigation in a larger sample.
- 25 August 2024
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 123, 143-150
Association between childhood abuse and risk of post-COVID-19 conditions: Results from three large prospective cohort studies
- 25 August 2024
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 123, 143-150
Association between childhood abuse and risk of post-COVID-19 conditions: Results from three large prospective cohort studies
- 1 March 2024
- Published by Wolters Kluwer Health in Harvard Review of Psychiatry
- Vol. 32 (2) , 47-57
Assessment and Treatment of Abnormal Involuntary Movements: A Clinically Focused Narrative Review
Learning Objectives: After participating in this CME activity, the psychiatrist should be better able to: • Categorize and describe different types of abnormal involuntary movements (AIMs). • Identify assessment tools and treatment options for AIMs. Abnormal involuntary movements (AIMs) comprise a diverse group of movement disorders characterized by uncontrolled and unintended movements (e.g., tremors, tics, dystonia). AIMs can occur at any stage of life and pose significant challenges for clinicians. It is difficult to determine their underlying causes due to the complex neurobiological mechanisms involved. Therefore, it is crucial to quantify the severity and progression of AIMs using well-validated measurement scales, such as the Abnormal Involuntary Movement Scale (AIMS). By employing reliable assessment approaches, clinicians can objectively evaluate the motoric manifestations of AIMs and track them over time. Treatment of AIMs varies depending on their nature and etiology. While AIMs often respond to treatment, serious side effects can undermine treatment efficacy. In this clinically focused narrative review, we categorize different types of AIMs and discuss their neurobiological aspects. Further, we emphasize the importance of using well-validated measurement scales for accurate assessment and discuss available treatment modalities that target the specific AIMs manifestations. Additionally, we cover the need for comprehensive care to address the multifaceted nature of AIMs, accounting for their physical manifestations as well as their psychological, social, and functional toll on patients. By embracing a multidisciplinary approach, health care professionals can provide patient-centered care that promotes overall well-being and enhances the lives of patients coping with AIMs. Regular follow-up assessments are necessary to monitor treatment response, adjust medications when needed, and provide ongoing support for individuals affected by AIMs.
- 1 March 2024
- Published by Wolters Kluwer Health in Harvard Review of Psychiatry
- Vol. 32 (2) , 47-57
Assessment and Treatment of Abnormal Involuntary Movements: A Clinically Focused Narrative Review
Learning Objectives: After participating in this CME activity, the psychiatrist should be better able to: • Categorize and describe different types of abnormal involuntary movements (AIMs). • Identify assessment tools and treatment options for AIMs. Abnormal involuntary movements (AIMs) comprise a diverse group of movement disorders characterized by uncontrolled and unintended movements (e.g., tremors, tics, dystonia). AIMs can occur at any stage of life and pose significant challenges for clinicians. It is difficult to determine their underlying causes due to the complex neurobiological mechanisms involved. Therefore, it is crucial to quantify the severity and progression of AIMs using well-validated measurement scales, such as the Abnormal Involuntary Movement Scale (AIMS). By employing reliable assessment approaches, clinicians can objectively evaluate the motoric manifestations of AIMs and track them over time. Treatment of AIMs varies depending on their nature and etiology. While AIMs often respond to treatment, serious side effects can undermine treatment efficacy. In this clinically focused narrative review, we categorize different types of AIMs and discuss their neurobiological aspects. Further, we emphasize the importance of using well-validated measurement scales for accurate assessment and discuss available treatment modalities that target the specific AIMs manifestations. Additionally, we cover the need for comprehensive care to address the multifaceted nature of AIMs, accounting for their physical manifestations as well as their psychological, social, and functional toll on patients. By embracing a multidisciplinary approach, health care professionals can provide patient-centered care that promotes overall well-being and enhances the lives of patients coping with AIMs. Regular follow-up assessments are necessary to monitor treatment response, adjust medications when needed, and provide ongoing support for individuals affected by AIMs.
- 18 January 2024
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 119 (3) , 692-701
Effect of multivitamin-mineral supplementation versus placebo on cognitive function: results from the clinic subcohort of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial and meta-analysis of 3 cognitive studies within COSMOS
- 18 January 2024
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 119 (3) , 692-701
Effect of multivitamin-mineral supplementation versus placebo on cognitive function: results from the clinic subcohort of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial and meta-analysis of 3 cognitive studies within COSMOS
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Moderation effects of APOE‐ε4 on marine omega‐3 fatty acids and its relation to change in cognitive function among community‐dwelling older adults
Background: In a recent trial, we observed no effect of omega‐3 fatty acids (omega‐3s) supplementation on cognitive decline. However, brain concentrations and metabolism of lipid molecules in response to omega‐3s may be regulated by apolipoprotein E (APOE)‐ε4 allele status. Further, while APOE‐ε4 is an established risk factor for Alzheimer disease, its association with cognitive decline is uncertain, especially in more diverse samples. The few randomized clinical trials (RCTs) addressing the moderation of effects of omega‐3s on cognitive decline by APOE‐ε4 have yielded inconsistent findings. Thus, we examined moderation by APOE‐ε4 on effects of omega‐3s vs. placebo for global and domain‐specific cognitive change over 2 years in a well‐characterized, diverse sample of older adults.Methods: VITamin D and OmegA‐3 TriaL (VITAL) is a 2×2 factorial RCT of vitamin D3 (2000 IU/day) and/or omega‐3s (1 g/day including 460 mg of eicosapentaenoic acid and 380 mg of docosahexaenoic acid) for cardiovascular disease and cancer prevention. We included 743 VITAL in‐clinic sub‐cohort participants who completed all cognitive tests at baseline and had APOE genotype data. The primary outcome was change in global cognition (averaging z‐scores of 9 tests) over 2 years; episodic memory and executive function/attention were examined separately. We used multiplicative interaction terms in general linear models of response profiles to examine moderation by APOE‐ε4 carrier status on effects of omega‐3s vs. placebo for cognitive change outcomes over 2 years.Results: The mean age (standard deviation) of participants was 67.1 (5.3) years; 50.6% were females; 13.5% were from racial and/or ethnic minority backgrounds; and 24.9% were APOE‐ε4 allele carriers. Over 2 years, compared with APOE‐ε4 non‐carriers, APOE‐ε4 carriers had faster declines in global cognition and episodic memory but not in executive function/attention; e.g., the mean difference in change (95% confidence interval) for episodic memory comparing APOE‐ε4 carriers vs. non‐carriers was ‐0.18 (‐0.33 to ‐0.03). There were no significant interactions between APOE‐ε4 carrier status and randomization status (omega‐3s vs. placebo) on change in global, episodic memory, or executive function/attention scores.Conclusion: APOE‐ε4 significantly predicted cognitive decline but did not modify the effect of omega‐3s on global and domain‐specific cognitive change over 2 years.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessModeration effects of APOE‐ε4 on marine omega‐3 fatty acids and its relation to change in cognitive function among community‐dwelling older adults
Background: In a recent trial, we observed no effect of omega‐3 fatty acids (omega‐3s) supplementation on cognitive decline. However, brain concentrations and metabolism of lipid molecules in response to omega‐3s may be regulated by apolipoprotein E (APOE)‐ε4 allele status. Further, while APOE‐ε4 is an established risk factor for Alzheimer disease, its association with cognitive decline is uncertain, especially in more diverse samples. The few randomized clinical trials (RCTs) addressing the moderation of effects of omega‐3s on cognitive decline by APOE‐ε4 have yielded inconsistent findings. Thus, we examined moderation by APOE‐ε4 on effects of omega‐3s vs. placebo for global and domain‐specific cognitive change over 2 years in a well‐characterized, diverse sample of older adults.Methods: VITamin D and OmegA‐3 TriaL (VITAL) is a 2×2 factorial RCT of vitamin D3 (2000 IU/day) and/or omega‐3s (1 g/day including 460 mg of eicosapentaenoic acid and 380 mg of docosahexaenoic acid) for cardiovascular disease and cancer prevention. We included 743 VITAL in‐clinic sub‐cohort participants who completed all cognitive tests at baseline and had APOE genotype data. The primary outcome was change in global cognition (averaging z‐scores of 9 tests) over 2 years; episodic memory and executive function/attention were examined separately. We used multiplicative interaction terms in general linear models of response profiles to examine moderation by APOE‐ε4 carrier status on effects of omega‐3s vs. placebo for cognitive change outcomes over 2 years.Results: The mean age (standard deviation) of participants was 67.1 (5.3) years; 50.6% were females; 13.5% were from racial and/or ethnic minority backgrounds; and 24.9% were APOE‐ε4 allele carriers. Over 2 years, compared with APOE‐ε4 non‐carriers, APOE‐ε4 carriers had faster declines in global cognition and episodic memory but not in executive function/attention; e.g., the mean difference in change (95% confidence interval) for episodic memory comparing APOE‐ε4 carriers vs. non‐carriers was ‐0.18 (‐0.33 to ‐0.03). There were no significant interactions between APOE‐ε4 carrier status and randomization status (omega‐3s vs. placebo) on change in global, episodic memory, or executive function/attention scores.Conclusion: APOE‐ε4 significantly predicted cognitive decline but did not modify the effect of omega‐3s on global and domain‐specific cognitive change over 2 years.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Effect of multivitamin‐mineral supplementation on change in cognitive function in the COSMOS Clinical subcohort and meta‐analysis of COSMOS cognition studies
Background: Few randomized clinical trials (RCTs) have investigated the effect of multivitamin‐mineral supplementation (MVM) on cognitive change among community‐dwelling older adults and effects remain untested using detailed in‐person, gold‐standard neuropsychological assessments; thus, we tested the effect of daily MVM vs. placebo on cognitive function among older adults enrolled in the in‐clinic component of COSMOS (COcoa Supplement and Multivitamin Outcomes Study). Furthermore, we conducted a meta‐analysis of the findings from the three COSMOS cognition studies: COSMOS‐Clinic (n = 603 for the detailed in‐person cognitive assessments), COSMOS‐Mind (n = 2262 for telephonic‐based cognitive assessments); and COSMOS‐Web (n = 3562 for computer‐based cognitive assessments) to provide a robust evaluation of the effects of MVM on cognition.Methods: COSMOS is a 2×2 factorial RCT of cocoa extract supplements (Mars Edge; containing 500 mg/day flavanols) and/or MVM (Haleon, as Centrum Silver) for cardiovascular and cancer prevention. In COSMOS‐Clinic, n = 573 of n = 603 COSMOS‐Clinic participants completed all cognitive tests at baseline; n = 492 completed all cognitive tests at both baseline and 2‐year follow‐up. The primary outcome was global cognitive score [averaging z‐scores of 11 tests: general cognition (the Modified Mini‐Mental State), episodic memory (Consortium to Establish a Registry for Alzheimer’s Disease [CERAD] word list learning and delayed recall tests; East Boston Memory Test immediate and delayed recall trials), CERAD word list recognition, and executive function/attention (two fluency tests; Trail Making Tests A and B; digit span backwards)]. Episodic memory and executive function/attention were examined separately. Finally, we used random‐effects models to meta‐analyze the findings of three COSMOS cognition studies.Results: In COSMOS‐Clinic, we observed a signal for effect of MVM vs. placebo on improvement in global cognition over two years (mean difference = 0.06, 95% confidence interval [CI]: ‐0.003, 0.12). MVM vs. placebo led to significant improvement in episodic memory (mean difference = 0.11, 95% CI: 0.001, 0.23) but not in executive function/attention (mean difference = 0.04, 95% CI: ‐0.04, 0.11). The meta‐analysis of three COSMOS studies showed significant benefits of MVM on global cognition and episodic memory (will be presented in detail).Conclusion: Daily MVM compared to placebo showed improvement in global cognition and episodic memory over 2 years among community‐dwelling older adults.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Open AccessEffect of multivitamin‐mineral supplementation on change in cognitive function in the COSMOS Clinical subcohort and meta‐analysis of COSMOS cognition studies
Background: Few randomized clinical trials (RCTs) have investigated the effect of multivitamin‐mineral supplementation (MVM) on cognitive change among community‐dwelling older adults and effects remain untested using detailed in‐person, gold‐standard neuropsychological assessments; thus, we tested the effect of daily MVM vs. placebo on cognitive function among older adults enrolled in the in‐clinic component of COSMOS (COcoa Supplement and Multivitamin Outcomes Study). Furthermore, we conducted a meta‐analysis of the findings from the three COSMOS cognition studies: COSMOS‐Clinic (n = 603 for the detailed in‐person cognitive assessments), COSMOS‐Mind (n = 2262 for telephonic‐based cognitive assessments); and COSMOS‐Web (n = 3562 for computer‐based cognitive assessments) to provide a robust evaluation of the effects of MVM on cognition.Methods: COSMOS is a 2×2 factorial RCT of cocoa extract supplements (Mars Edge; containing 500 mg/day flavanols) and/or MVM (Haleon, as Centrum Silver) for cardiovascular and cancer prevention. In COSMOS‐Clinic, n = 573 of n = 603 COSMOS‐Clinic participants completed all cognitive tests at baseline; n = 492 completed all cognitive tests at both baseline and 2‐year follow‐up. The primary outcome was global cognitive score [averaging z‐scores of 11 tests: general cognition (the Modified Mini‐Mental State), episodic memory (Consortium to Establish a Registry for Alzheimer’s Disease [CERAD] word list learning and delayed recall tests; East Boston Memory Test immediate and delayed recall trials), CERAD word list recognition, and executive function/attention (two fluency tests; Trail Making Tests A and B; digit span backwards)]. Episodic memory and executive function/attention were examined separately. Finally, we used random‐effects models to meta‐analyze the findings of three COSMOS cognition studies.Results: In COSMOS‐Clinic, we observed a signal for effect of MVM vs. placebo on improvement in global cognition over two years (mean difference = 0.06, 95% confidence interval [CI]: ‐0.003, 0.12). MVM vs. placebo led to significant improvement in episodic memory (mean difference = 0.11, 95% CI: 0.001, 0.23) but not in executive function/attention (mean difference = 0.04, 95% CI: ‐0.04, 0.11). The meta‐analysis of three COSMOS studies showed significant benefits of MVM on global cognition and episodic memory (will be presented in detail).Conclusion: Daily MVM compared to placebo showed improvement in global cognition and episodic memory over 2 years among community‐dwelling older adults.